
    
      High dose MVAC and Cisplatin/Gemcitabine combination regimens have shown comparable efficacy
      in the first line treatment of advanced or metastatic bladder cancer, whereas the latter
      regimen has better tolerability. The efficacy and tolerability of the sequential
      administration of these two regimens is not known.
    
  